Inhibrx Biosciences, Inc. — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Inhibrx announced updated Phase 1/2 data for ozekibart (INBRX-109) combined with irinotecan/temozolomide in relapsed/refractory Ewing sarcoma: 62.7% ORR (2 CRs, 30 PRs out of 51 response-evaluable patients), 86.3% DCR, and 6.0-month mPFS as of September 18, 2026 cutoff (60 patients enrolled, 22 on active treatment). These results substantially exceed historical benchmarks of 15–30% ORR and 3–4 month mPFS. The company also noted FDA acceptance of a BLA for ozekibart in conventional chondrosarcoma.
Why this rating
Strong Phase 1/2 efficacy data in oncology is material for a $174.6M clinical-stage biotech; positive results de-risk development and strengthen FDA discussions for rare sarcoma indications.
Tradability signal
NO TRADE
No trade: positive news with only -0.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.03% over 4 hrs, n=232). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $74.18 ▲ 0.32% | at our read · unknown $73.94 | +10 min · unknown $73.52 ▼ 0.57% | +30 min · unknown $73.83 ▼ 0.16% | +1 hr · unknown $73.22 ▼ 0.98% | +4 hrs · unknown $72.28 ▼ 2.24% |
The stock had already moved -0.32% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.